Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Shares Purchased by State Street Corp

State Street Corp raised its stake in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) by 6.4% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 449,975 shares of the biotechnology company’s stock after buying an additional 27,147 shares during the quarter. State Street Corp’s holdings in Enanta Pharmaceuticals were worth $4,662,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of ENTA. Erste Asset Management GmbH purchased a new stake in shares of Enanta Pharmaceuticals in the 3rd quarter valued at approximately $1,243,000. Point72 Asset Management L.P. purchased a new stake in Enanta Pharmaceuticals in the third quarter valued at approximately $903,000. Walleye Capital LLC lifted its stake in Enanta Pharmaceuticals by 96.4% during the third quarter. Walleye Capital LLC now owns 43,899 shares of the biotechnology company’s stock worth $455,000 after purchasing an additional 21,550 shares in the last quarter. Valence8 US LP purchased a new position in shares of Enanta Pharmaceuticals during the third quarter worth $207,000. Finally, Cubist Systematic Strategies LLC grew its stake in shares of Enanta Pharmaceuticals by 65.8% in the second quarter. Cubist Systematic Strategies LLC now owns 45,350 shares of the biotechnology company’s stock valued at $588,000 after buying an additional 18,003 shares in the last quarter. Institutional investors and hedge funds own 94.99% of the company’s stock.

Insider Transactions at Enanta Pharmaceuticals

In other news, CEO Jay R. Luly sold 5,142 shares of the business’s stock in a transaction that occurred on Friday, December 6th. The shares were sold at an average price of $8.06, for a total transaction of $41,444.52. Following the completion of the sale, the chief executive officer now owns 801,638 shares in the company, valued at approximately $6,461,202.28. The trade was a 0.64 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 13.64% of the company’s stock.

Enanta Pharmaceuticals Trading Up 0.2 %

NASDAQ:ENTA opened at $6.01 on Monday. Enanta Pharmaceuticals, Inc. has a 12-month low of $5.70 and a 12-month high of $17.80. The firm has a market cap of $127.38 million, a PE ratio of -1.10 and a beta of 0.49. The stock has a fifty day moving average price of $9.15 and a 200 day moving average price of $11.46.

Enanta Pharmaceuticals (NASDAQ:ENTA) last posted its quarterly earnings results on Monday, November 25th. The biotechnology company reported ($1.36) EPS for the quarter, missing the consensus estimate of ($1.16) by ($0.20). The firm had revenue of $14.60 million for the quarter, compared to analyst estimates of $17.99 million. Enanta Pharmaceuticals had a negative return on equity of 73.02% and a negative net margin of 171.57%. The company’s revenue was down 22.8% on a year-over-year basis. During the same quarter last year, the firm earned ($1.33) EPS. Equities analysts forecast that Enanta Pharmaceuticals, Inc. will post -4.73 EPS for the current year.

Analyst Ratings Changes

ENTA has been the topic of several research reports. HC Wainwright decreased their target price on Enanta Pharmaceuticals from $27.00 to $18.00 and set a “buy” rating on the stock in a research note on Tuesday, December 24th. JMP Securities reiterated a “market outperform” rating and set a $21.00 price target (down from $22.00) on shares of Enanta Pharmaceuticals in a research note on Tuesday, November 26th. Finally, Robert W. Baird lowered their price objective on shares of Enanta Pharmaceuticals from $26.00 to $20.00 and set an “outperform” rating for the company in a research note on Tuesday, November 26th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, three have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Enanta Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $17.25.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.